About us
Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer.
Kancera works on the development of drugs, starting with new treatment concepts and ending with a drug candidate. At Kancera, we also develop cancer models and stem cell-based techniques that make it possible to study the effect of the candidates, long before start of clinical trials.
Operations are conducted in specially designed ultra-modern facilities at the Karolinska Institutet Science Park in Solna, close to Stockholm City.
Our strengths
- Meeting the increasing market demand for drug candidates
- An experienced Board of Directors, management and organization
- Two drug candidates with great potential under development
- A union of industrial and clinical expertise
- Access to an internationally validated product development capacity which makes the risky pharmaceutical development more precise
Historical background
During 2006, Pharmacia and Biovitrum's unit for the development of drug candidates was spun off to iNovacia AB. In 2008, a partnership began with the Cancer Centre Karolinska (CCK). This was later followed by a partnership with Sprint Bioscience, a company that specializes in structure-based pharmaceutical design.
In May 2010, iNovacia, Sprint Bioscience, expertise from the Karolinska Institute, and a group of private investors, founded Kancera AB through the infusion of capital and two pharmaceutical projects focusing on cancer that had been developed individually and jointly since 2003 and 2007, respectively.